Business Context and Reporting Period
This Form 8-K was filed by Aldeyra Therapeutics, Inc. on June 19, 2014. The report discloses the appointment of a new Chief Financial Officer effective June 23, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Stephen Tulipano as Chief Financial Officer and principal financial and accounting officer. Mr. Tulipano brings prior experience as CFO of Javelin Pharmaceuticals, Inc. (2006-2010) and Director of Corporate Accounting at Biogen Idec, Inc. (1998-2006).
Management Commentary and Compensation
Mr. Tulipano's compensation package includes:
- Base Salary: $260,000 per year.
- Annual Bonus: Target payout of 30% of base salary.
- Equity Grant: 67,642 shares of common stock under the 2013 Equity Plan, vesting over four years.
- Other: Standard employee benefit plans and programs.
The Company entered into an offer letter and invention assignment agreement, with an indemnification agreement to follow.
Investor Verification Checklist
- Confirm the effective start date of Mr. Tulipano's role (June 23, 2014).
- Verify the vesting schedule and terms of the 67,642 stock option grant.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Check subsequent filings for any changes to the Company's financial reporting structure under the new CFO.